Background: A recent neurocognitive model of attention-deficit hyperactivity disorder (ADHD) has proposed a primary deficit in reward function as well as in executive function to account for underlying neural substrates of ADHD symptoms. Atomoxetine has been widely used as a non-stimulant medication for ADHD with little abuse liability. Although animal studies have reported that atomoxetine increases extracellular levels of both noradrenaline and dopamine in the prefrontal cortex, which receives input from a mesocorticolimbic pathway involved in reward function, there have been few studies in humans concerning the effects of atomoxetine in terms of reward function. Therefore, we investigated whether a single dose of atomoxetine (acute atomoxetine) affects reward processing in healthy adults.
Introduction
Attention-deficit hyperactivity disorder (ADHD) is characterized by symptoms that include inattention, hyperactivity, and impulsivity 1 . These symptoms have so far been thought to arise from a primary deficit in executive function with higher-level and top-down cognitive processes 2 . A meta-analysis of functional magnetic resonance imaging (fMRI) studies revealed that patients with ADHD show hypoactivity in the frontoparietal network, which supports goal-directed executive processes and guides decision-making 3 . On the other hand, a substantial proportion of patients with ADHD has few impairments in executive function measures 4 . Another neurocognitive model has also proposed the crucial involvement of abnormal reward functions as well as executive dysfunction to account for underlying neural mechanisms of the ADHD symptoms 5, 6 . For example, it has been reported that patients with ADHD exhibit delay aversion characterized by attempts to escape or avoid delay, and that children with ADHD show a greater preference to select a small but immediate reward than a larger and delayed one compared to normal controls 7 , suggesting a possible involvement of reward dysfunction related to impulsivity, a canonical symptom of ADHD.
Reward has several external and internal components that ensure adequate reward functions in association with responsible neural substrates 8 . The key brain substrates for reward functions occur in two midbrain dopamine (DA) pathways 8 -the nigrostriatal pathway projecting from the substantia nigra to the caudate nucleus and putamen, and the mesocorticolimbic pathway consisting of ventral tegmental area (VTA) projections to the nucleus accumbens (NAc) and PFC 9 . It has been reported that aberrant substantia nigra/VTA novelty processing plays an important role in the suboptimal rewardrelated decision-making in ADHD 10 . Several reports showed that the activity in the ventral striatum was decreased during reward anticipation in ADHD 11, 12 , although another large-scale study using a similar task reported no substantial change in activation in the ventral striatum 13 .
As for the mesocorticolimbic pathway, activities in fronto-striatal circuitry are reportedly increased during anticipation and reward acquisition in ADHD 13 , and the impaired signal from VTA to ACC pathway is hypothesized to lead to impaired reinforcement learning processing 14 .
Atomoxetine is a selective noradrenaline (NA) reuptake inhibitor 15 and is used as a non-stimulant medication for ADHD. In clinical practice, atomoxetine improves various executive functions in adults and children with ADHD 16, 17 . An fMRI study reported that atomoxetine decreased activation in the dorsal ACC and dorsolateral PFC during the counting Stroop task in association with improvement of focused attention in patients with ADHD 18 . On the other hand, atomoxetine normalizes performance by enhancing the activity in the dorsolateral PFC in the working memory task in patients with ADHD 19 . These results suggest that atomoxetine can normalize dysregulated executive function in PFC in patients with ADHD.
While atomoxetine does not increase extracellular levels of either NA or DA in NAc 20 , it increases extracellular levels of both NA and DA in PFC 20, 21 . Pharmacological manipulation of the NA level with atomoxetine affects exploration of reward-options in humans 22 . Therefore, atomoxetine may modulate some reward functions in PFC through dopaminergic and/or noradrenergic transmission.
In the present study, we investigated whether a single 25 27 . Here, we show specific regions involved in reward function that are affected by a singledose of atomoxetine (acute atomoxetine) using the MID task with fMRI.
Materials and Methods

Participants
Twenty physically and psychiatrically healthy participants (9 females, 11 males; mean age and standard deviation [SD], 31.4 and 5.6 years) were recruited for the study. Before starting the experiment, we excluded subjects whose baseline mood scores or subjective states exceeded the set criteria (see subjective ratings below).
All participants were right-handed according to the Edinburgh Handedness Inventory
28
, and none used any drug, had a medical history of psychiatric disorders, or were allergic to atomoxetine. They were instructed to abstain from caffeine and alcohol intake for 48 and 24
hours, respectively, prior to the experiment to avoid their effects on physical and cognitive performance 29 .
Over the course of the study, we excluded 6 participants. One was ruled out after deciding to discontinue participation, two for high caffeine concentration in urine (exceeding 2 μg/mL), one for excessive head movement (i.e., more than 2 mm in any direction), one for excessive head movement and excessive button pressing during Fig. 1 Structure of the monetary incentive delay task Gain (+¥20, +¥100, and +¥500), loss (-¥20, -¥100, and -¥500), neutral (+¥0 and -¥0), and no response (triangle) cues were presented pseudo-randomly within each run. In each trial, each one of nine cues, delay (anticipation period), target, delay, and feedback (outcome period) was sequentially presented.
the MID task, and one for excessive head movement and unknown caffeine concentration in urine due to sample collection failure. The excessive count of button presses during the MID task was based on the ratio of the number of button presses with short reaction time below 150 ms to the number of all targets requiring the button press (n = 144) 30 . 
Subjective Ratings
To assess baseline mood and subjective states of the participants, they underwent 2 psychological tests: Beck Depression Inventory (BDI) 32, 33 and State-Trait Anxiety Inventory (STAI) 34 . Transient subjective mood states were also evaluated by 16 items (e.g., alert, calm, strong, clearheaded, well-coordinated, etc.) with visual analogue scales before and 1 hour after drug administration 35 . Subjects with scores of BDI>11, STAI-state>45, or STAI-trait> 46 were excluded from the study, as high depression and anxiety scores may affect brain activity in reward processing and reward-related behaviors 36, 37 .
Experimental Design
The experiment was designed as a randomized, placebo-controlled within-subjects cross-over trial. To carefully monitor adverse drug reactions in participants, we conducted the current study in a single-blind manner.
The participants took a single dose of atomoxetine (40 mg in a Strattera capsule formula, Eli Lilly, Japan) or placebo capsule (same shape, the latter containing lactose) in the first series. The participants given atomoxetine for the first series were given the placebo, and those given the placebo in the first series were given atomoxetine during the second series of the study. The washout period was at least a one week between the first and second series.
They were asked not to eat or drink anything except water from 2 h prior to, and throughout the experiment.
The fMRI study started 1.5 h after drug administration, at which time the peak level of atomoxetine in plasma would be expected 38, 39 .
Monetary Incentive Delay Task
We used the MID task to examine neural responses to monetary anticipation and outcome 40 42 . Participants were informed that they would receive a gift voucher according to the amount of money they had earned during the task. The task consisted of 2 sessions totaling 180 trials ( 
MRI Data Acquisition
All imaging data were collected on an Intera Achieva fMRI studies using the MID task 40, 43 . The vmPFC ROI was defined based on the anatomically and functionally defined areas 26, 27 . The vmPFC ROI was extracted using the Wake Forest University PickAtlas. One single NAc ROI was anatomically defined by bilateral NAc templates using the Wake Forest University PickAtlas. For group-level analyses, the one-sample t test was performed to determine group-level activation for each contrast. Then, for group comparisons, paired t test was performed to assess the difference between the placebo and atomoxetine administrations. The contrast images obtained from subjectlevel statistical analyses were entered into paired t test analyses. The ROIs were analyzed at a family-wise error (FWE)-corrected p<0.05 using small volume correction.
The percent signal change within vmPFC ROI was calculated for the contrast of "hit" versus "miss" during the gain outcome period using MarsBaR. The values of percent signal change with gain outcome under placebo and atomoxetine conditions were analyzed using the paired t 
Results
Effect of Atomoxetine on Subjective Mood States
We examined changes in subjective mood before and after drug administration, as atomoxetine or noradrenergic agents may modulate mood 44 46 .
Changes in subjective mood rating were calculated by subtracting the values before drug administration from those at 1 h after drug administration. There was no significant difference in subjective mood states between placebo and atomoxetine. These results suggest that a single dose of atomoxetine does not modify mood states.
Effects of Atomoxetine on Task Performance
During the MID task (Fig. 1) , we examined the effects of atomoxetine on reaction time, hit rate, and total sum earned by participants ( Table 1) . No significant difference was observed in mean reaction time and total amount of money earned between placebo and atomoxetine conditions. The mean hit rate, however, showed a significant decrease under atomoxetine as compared to placebo.
Effect of Atomoxetine on Brain Activation During Gain Outcome and Gain Anticipation
We focused on vmPFC for gain outcome and NAc for gain anticipation as a priori ROI based on previous fMRI studies using the MID task 40, 43 and examined the effect of atomoxetine on brain activation. Under both placebo and atomoxetine conditions, a significant activation in the left vmPFC was observed during gain outcome (p<0.05 FWEcorrected for vmPFC ROI), consistent with a previous study 26, 43 ( Table 2) .
Group-level analysis revealed that atomoxetine showed a significant decrease in the left vmPFC activation during gain outcome as compared with placebo (p<0.05 FWEcorrected for vmPFC ROI) ( Table 2 and Figure 2, 3) . Fig. 2 Neural responses to gain outcome in the ventral medial prefrontal cortex (A) Brain activation in the ventral medial prefrontal cortex during gain outcome ("hit" versus "miss" outcomes in potential gain trials) under placebo and (B) atomoxetine conditions. Familywise error-corrected p<0.05 for the ROI in the ventral medial prefrontal cortex. Color bars indicate t statistics. Fig. 3 Effects of atomoxetine on neural responses to gain outcome Atomoxetine reduced activation in the ventral medial prefrontal cortex during gain outcome compared to placebo. Familywise error-corrected p<0.05 for the ROI in the ventral medial prefrontal cortex. Color bar indicates t statistics. Fig. 4 Percent signal changes in ventral medial prefrontal cortex (vmPFC) during gain outcome Percent signal changes from vmPFC ROI were calculated for the contrast of "hit" versus "miss" during gain outcome. *p<0.05.
We then examined the percent signal change in bloodoxygenation-level dependent signal in vmPFC during gain outcome (Fig. 4) . In gain outcome, atomoxetine showed a lower activation than placebo (p=0.027). Next, we investigated the activity of gain anticipation in NAc.
In gain anticipation, the left NAc activation under placebo and bilateral NAc activation under atomoxetine were increased ( Table 2) . Group-level analyses revealed that atomoxetine did not show any significant increase in NAc activation during gain anticipation compared with placebo (p<0.05 FWE-corrected for NAc ROI).
Consistent with previous studies 27, 43 , whole-brain analysis during gain outcome under placebo condition showed a significant increase in activation in the caudate, putamen, and amygdala as well as in vmPFC (p<0.001 uncorrected) ( Table 3) . Similarly, there were no significant correlations between 
Discussion
We showed that atomoxetine significantly decreased brain activation in vmPFC during reward outcome compared with placebo, while it did not affect NAc activity during reward anticipation.
A meta-analysis of functional neuroimaging studies with MID task revealed that ventral striatum, vmPFC including medial orbitofrontal cortex, posterior cingulate cortex, and amygdala showed preferential activation during successful reward outcome as compared with unsuccessful reward outcome or neutral outcome 27 . Consistently, vmPFC and amygdala were activated during reward outcome in the present study. As for MID task, vmPFC activity increased when participants expected and obtained larger reward, whereas it decreased when they expected, but did not obtain the reward 25, 26 . The present result also showed that vmPFC activation during reward outcome was larger under both placebo and atomoxetine when the participants obtained larger reward as compared with when they missed the reward. In addition, because the activation in vmPFC, as well as in NAc, did not show any significant correlations with performance under both conditions, it is unlikely that the behavioral differences could be the cause of the different brain activity. Therefore, these results suggest that the activation in vmPFC during reward outcome encodes the reward value.
Imaging studies of ADHD have so far focused on dysfunction in the ventral striatum during reward anticipation 11, 12 . A large-scale study using the MID task has shown enhanced neural responses in fronto-striatal circuitry to anticipation and acquisition of reward in ADHD 13 . In addition, patients with ADHD have a tendency to prefer immediate reward and avoid delayed reward 7, 47 . This tendency may cause impulsive behavior, as they are unable to wait for the outcome, or their atten-tion is distracted due to the reward delay 6 . Given that medial PFC activity is related to encoding of the expected reward value 48, 49 , PFC hyperactivity in ADHD might represent overestimation of the immediate reward or preparation for the next reward opportunity.
In the present study, we observed that atomoxetine significantly decreased brain activation in vmPFC during reward outcome compared with placebo. Previous studies using fMRI have reported that atomoxetine normalizes both abnormal activation and deactivation in executive function in ADHD 18, 19 . Therefore, although the results observed in healthy adults should be carefully interpreted, the present study suggests that atomoxetine acts on vmPFC and might be beneficial for a group of patients with hyperactivity in vmPFC.
Atomoxetine did not significantly increase activation in On the other hand, it has been reported that atomoxetine increases extracellular levels of DA in PFC, but not in the striatum and NAc 20 . Activation of DA transmission in reward function, particularly the VTA-NAc pathway, is critical for the development of addiction 51 . The difference in effect on DA in the striatum and NAc may explain the difference in abuse potential between methylphenidate and atomoxetine 52 54 .
As for task performance, atomoxetine significantly reduced the hit rate during the task in the present study. It has been reported that low to moderate levels of NA and DA have a beneficial effect on working memory in PFC, whereas high concentrations of NA and DA in PFC impair such executive function 55 . Consistently, 80 mg of atomoxetine reportedly increases failure of response inhibition during Go/NoGo task 24 , while 60 mg of atomoxetine improves inhibition control during stop-signal task 56 . It has been reported that DA receptor agonists improved cognition in subjects with lower baseline cognitive ability in pre-treatment state, but that it worsens in those with higher baseline capacity 57 , showing that the relationship between cognitive performance and DA levels follows an "inverted-U-shaped" function. Moreover, a similar "inverted-U-shaped" effect has been reported with NA 55 .
Atomoxetine increases extracellular levels of both NA and DA in PFC 20, 21 . Therefore, reduced performance might be due to the increase in NA and DA levels in PFC be- 
